An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

NCT01773421 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Inc.